Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
23 Leser
Artikel bewerten:
(0)

Global Human Microbiome Therapeutics Market 2018-2022: Market to Grow at a CAGR of 14.19% - Growing Investments from Venture Capitalists

DUBLIN, Jan. 4, 2018 /PRNewswire/ --

The "Global Human Microbiome Therapeutics Market 2018-2022" report has been added to Research and Markets' offering.

Research and Markets Logo

The global human microbiome therapeutics market to grow at a CAGR of 14.19% during the period 2018-2022.

Global Human Microbiome Therapeutics market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

According to the report, one of the major drivers for this market is side effects of the existing treatments. Various medicines available in the market have several side-effects including minor headaches. These medicines may also impart serious side-effects such as liver or kidney injury, heart problems, and even death.

The seriousness of side-effects drives the need for innovative treatment technologies, such as human microbiome therapeutics, that have reduced the negative impact on the human body. The demand for microbiome therapeutics is increasing since it provides treatment sans chemicals.

The latest trend gaining momentum in the market is growing investments from venture capitalists. Venture capitalists are capitalizing on the need for effective treatment and are offering therapeutic treatment solutions to treat disorders such as autoimmune disorders, infections, and cancer.

Investments from venture capitalists towards microbiome therapeutics is exponentially boosting the growth of the microbiome sequencing therapeutics market. Vedanta Biosciences is already collaborating with NYU Langone Medical Center to develop novel microbiome- derived immunotherapies for cancer patients.

Key vendors

  • Enterome Bioscience
  • Rebiotix
  • Seres Therapeutics
  • Vedanta Biosciences

Other prominent vendors

  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Takeda Pharmaceutical

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Market Landscape

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Pipeline Landscape

Part 09: Market Segmentation By Therapeutic Application

Part 10: Customer Landscape

Part 11: Regional Landscape

Part 12: Decision Framework

Part 13: Drivers And Challenges

Part 14: Market Trends

Part 15: Vendor Landscape

Part 16: Vendor Analysis

Part 17: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/hq5d44/global_human?w=5

Media Contact:


Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2018 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.